School of Medicine, University of Electronic Science and Technology of China.
GCP Institution, Chengdu Women's and Children's Center Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
J Pept Sci. 2022 Dec;28(12):e3443. doi: 10.1002/psc.3443. Epub 2022 Jul 31.
Peptides have gained popularity in the global market during recent years and have been placed between small molecule drugs and biologics. However, little is known about the comprehensive landscape of peptide drugs in obstetrics and gynaecology. Herein, we analysed new peptide drug-related clinical trials in obstetrics and gynaecology registered on ClinicalTrials.gov. The number and percentage were used for statistical analysis, and a time trend analysis was conducted by calculating the annual growth rate. We aimed to provide the first overview of the changing landscape and status of global peptide drugs in this prospective field, including exploring drug targets, the cutting-edge oncotherapy of peptide vaccines and peptide-drug conjugates, and unsolved challenges with oral administration.
近年来，肽在全球市场上越来越受欢迎，它们处于小分子药物和生物制剂之间。然而，人们对妇产科肽类药物的全貌知之甚少。在此，我们分析了 ClinicalTrials.gov 上注册的妇产科新的肽类药物相关临床试验。采用数量和百分比进行统计分析，并通过计算年增长率进行时间趋势分析。我们旨在提供该前瞻性领域中全球肽类药物不断变化的概况和现状的第一概述，包括探索药物靶点、肽疫苗和肽偶联药物的前沿肿瘤治疗以及口服给药的未解决挑战。
